Efficacy News and Research

RSS
IMO-4200 dual agonist increases antitumor activity in lymphoma models: Study

IMO-4200 dual agonist increases antitumor activity in lymphoma models: Study

Encouraging data from perifosine Phase 2 studies in advanced leukemia, Hodgkin's lymphoma

Encouraging data from perifosine Phase 2 studies in advanced leukemia, Hodgkin's lymphoma

Clinical trial results of ACY-1215 in multiple myeloma published in scientific journal of ASH

Clinical trial results of ACY-1215 in multiple myeloma published in scientific journal of ASH

NIH scientists consider prospects for universal influenza vaccine

NIH scientists consider prospects for universal influenza vaccine

Positive interim data from Phase I/II trial of CYT387 in myelofibrosis presented at ASH Annual Meeting

Positive interim data from Phase I/II trial of CYT387 in myelofibrosis presented at ASH Annual Meeting

Drug prescribed for Parkinson's disease may also treat restless leg syndrome: MCG researchers

Drug prescribed for Parkinson's disease may also treat restless leg syndrome: MCG researchers

New analysis of Soliris in patients with PNH presented at ASH Annual Meeting

New analysis of Soliris in patients with PNH presented at ASH Annual Meeting

FDA accepts for review Bristol-Myers Squibb's ORENCIA sBLA for severe RA

FDA accepts for review Bristol-Myers Squibb's ORENCIA sBLA for severe RA

VIVUS reports positive results from avanafil phase 3 study in erectile dysfunction

VIVUS reports positive results from avanafil phase 3 study in erectile dysfunction

NovaBay Pharmaceuticals, Galderma expand their multi-year collaboration agreement

NovaBay Pharmaceuticals, Galderma expand their multi-year collaboration agreement

MenAfriVac to help health workers eliminate meningococcal A epidemics

MenAfriVac to help health workers eliminate meningococcal A epidemics

Telik announces positive results from Phase 2 trial of ezatiostat in patients with MDS

Telik announces positive results from Phase 2 trial of ezatiostat in patients with MDS

Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH

Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH

Genentech announces Phase II study results of RG1678 for treatment of schizophrenia

Genentech announces Phase II study results of RG1678 for treatment of schizophrenia

New research focusing on VTE presented at ASH Annual Meeting

New research focusing on VTE presented at ASH Annual Meeting

Research on BCR-ABL inhibitors for treating ALL, CML presented at ASH Annual Meeting

Research on BCR-ABL inhibitors for treating ALL, CML presented at ASH Annual Meeting

First patient dosed with rFVIIIFc in A-LONG trial

First patient dosed with rFVIIIFc in A-LONG trial

Amgen announces final study results of Nplate in adults with chronic ITP

Amgen announces final study results of Nplate in adults with chronic ITP

Cell Therapeutics announces new pixantrone EOS follow up results

Cell Therapeutics announces new pixantrone EOS follow up results

Immunomedics reports results of milatuzumab-based combination treatments for NHL patients

Immunomedics reports results of milatuzumab-based combination treatments for NHL patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.